BISOXATIN

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H15NO4
Molecular Weight	333.3374
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC1=CC=C(C=C1)C2(OC3=CC=CC=C3NC2=O)C4=CC=C(O)C=C4

InChI

InChIKey=BPKUDUSVDVLOPY-UHFFFAOYSA-N

InChI=1S/C20H15NO4/c22-15-9-5-13(6-10-15)20(14-7-11-16(23)12-8-14)19(24)21-17-3-1-2-4-18(17)25-20/h1-12,22-23H,(H,21,24)

HIDE SMILES / InChI

Description
Sources: http://repository.kulib.kyoto-u.ac.jp/dspace/bitstream/2433/205764/1/ngh033006_1122.pdf
Curator's Comment: description was created based on several sources, including http://bijsluiters.fagg-afmps.be/registrationSearchServlet?key=BE022924&leafletType=leafletFR

Bisoxatin (Laxonalin, Wylaxine) acetate is a stimulant laxative that has been used in the treatment of constipation. The drug showed good effects to habitual constipation and dolichocolon but was not sufficient acting in megacolon. It seems that the drug is effective to constipation due to functional disorders but the effect is not sufficient to constipation caused chiefly by organic colonic changes. No side effect was observed even in long term administration.

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Constipation 112 Sources: http://www.ncbi.nlm.nih.gov/pubmed/4996225/	Primary		Approved 8429	Wylaxine Approved Use Wylaxine is recommended for the treatment of constipation symptoms (non-mechanical origin only) and for preparing a gastrointestinal examination.

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

120 mg in the evening at bedtime

Route of Administration: Oral

In Vitro Use Guide

Unknown

Name

Type

Language

BISOXATIN

Official Name

English

bisoxatin [INN]

Common Name

English

Bisoxatin [WHO-DD]

Common Name

English

2,2-BIS(P-HYDROXYPHENYL)-2H-1,4-BENZOXAZIN-3(4H)-ONE

Common Name

English

Classification Tree Code System Code

WHO-VATC

QA06AB09